Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients: A Randomized Trial

By M. Roizen. 2010

872 citations recorded by the source corpus.

Subfields: Anesthesiology and Pain Medicine, Critical Care and Intensive Care Medicine, Developmental Neuroscience

View Paper: https://www.semanticscholar.org/paper/a9a91c386b5138ceade66327771665a25886bddf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Anesthesiology and Pain Medicine

1. S. Mcgrane
2. Mayur B. Patel
3. E. W. Ely
4. A. Marra
5. Shruti B. Patel
6. Christopher G Hughes
7. J. Kress
8. Pratik Pandharipande

In Critical Care and Intensive Care Medicine

1. Pratik Pandharipande
2. S. Mcgrane
3. Christopher G Hughes
4. J. Kress
5. Mayur B. Patel
6. E. W. Ely
7. A. Marra
8. Shruti B. Patel

In Developmental Neuroscience

1. S. Mcgrane
2. Mayur B. Patel
3. E. W. Ely
4. A. Marra
5. Shruti B. Patel
6. Christopher G Hughes
7. J. Kress
8. Pratik Pandharipande

Citations in the corpus

• Days of delirium are associated with 1-year mortality in an older intensive care unit population. (2009, background): “A recent randomized controlled trial demonstrated that patients who received dexmedetomidine versus midazolam for sedation had less delirium (40).”
• Sedation and analgesia in the mechanically ventilated patient. (2012, background): “The primary significant side effects of dexmedetomidine infusion are bradycardia and hypotension, which may be mitigated by avoiding a loading dose and initiating a slow infusion rate (86, 96).”
• Sedation in the intensive care setting (2012, positive): “While bradycardia was a common side effect that occurred in the MENDS, SEDCOM, and MIDEX studies, there were no significant differences between the comparator groups with regards to bradycardia necessitating treatment.(58,59,73) Furthermore, neither bradycardia nor hypotension was significantly diff”
• Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine (2017, background): “1 Intensive Care Unit Sedation and Delirium Although the US Food and Drug Administration approved dexmedetomidine for use up to 24 h only, multiple studies showed an acceptable safety profile when using continuous dexmedetomidine sedation up to 30 days in ICU patients [58, 59].”
• The ABCDEF Bundle in Critical Care (2017, positive): “the duration of mechanical ventilation in patients sedated with dexmedetomidine compared with midazolam.(30) The MENDS study (Maximizing Efficacy of Targeted Sedation and Reducing Neurologic Dysfunction) evaluated the role of changing sedation paradigms on acute brain dysfunction, comparing dexmedet”